MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.

This clinical trial summary provides the background and rationale for a randomized trial, MAGRIT, to investigate the efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) agents in preventing cancer relapse, when administered after tumor resection, in patients with MAGE-A3-positive stages IB, II, and IIIA non-small-cell lung cancer. The study will also evaluate potential side effects of MAGE-A3 ASCIs. The primary endpoint is disease-free survival. The secondary endpoint is prospective validation of the gene signature predictive of benefit from MAGE-A3 ASCI therapy.

RCT Entities:   Population Interventions Outcomes